The protein MYSM1 (MYB-like, SWIRM, and MPN domains 1) is a histone H2A deubiquitinase that augments the activity of cisplatin in triple-negative breast cancer (TNBC) cells by suppression of p90 ribosomal S6 kinase 3 (RSK3) and induction of apoptosis mediated by activated BCL2 antagonist of cell death (BAD)[49]. This evidence concerns the gene MYSM1 and triple-negative breast carcinoma.